Patient Eligibility
BETMIGA™ 25 mg and BETMIGA™ 50 mg tablet active ingredient, Mirabegron is a selective beta 3-adrenoceptor agonist.
Please answer the following questions to determine if your patient is eligible for BETMIGA™.
Does the patient have uncontrolled hypertension ≥ 180/110mm Hg?
*
Yes
No
What is the patient's most recent eGFR?
*
30-89 ml/min/1.73m2
15 - 29 ml/min/1.73m2
< 15ml/min//1.73m2
What is the patient's most recent hepatic impairment determination?
*
No hepatic impairment
Mild hepatic impairment (Child Pugh class A)
Moderate hepatic impairment (Child Pugh class B)
Severe hepatic impairment (Child Pugh class C)
Next